S M Gollin1. 1. Department of Human Genetics, University of Pittsburgh Graduate School of Public Health, University of Pittsburgh, Pennsylvania 15261, USA. sgollin@helix.hgen.pitt.edu
Abstract
BACKGROUND: Cytogenetic alterations underlie the development of squamous cell carcinomas of the head and neck (SCCHN). Because many of the molecular genetic changes in SCCHN result from chromosomal alterations, a complete perspective on the genetic changes in tumors requires a basic introduction to cytogenetics. This review presents a brief description of the latest cytogenetic techniques and a description of chromosomal alterations in SCCHN, their molecular correlates, and clinical implications. RESULTS: The most frequent cytogenetic alterations in SCCHN are gains of 3q, 8q, 9q, 20q, 7p, 11q13, and 5p and losses of 3p, 9p, 21q, 5q, 13q, 18q, and 8p. The karyotypes often provide an explanation for the mechanism by which the molecular genetic alterations arose. For example, the coordinate gains and losses involving whole arms of chromosomes 3, 5, 7, 8, and 9 often result from isochromosome formation. In addition, apparent allelic imbalances may not represent loss of heterozygosity but gene amplification. These results suggest that cytogenetic analysis is valuable for placing the molecular genetic findings in perspective at the cellular level. CONCLUSIONS: Cytogenetic endpoints may be useful tools for dissecting clinical differences in tumor behavior and response to therapy. Numerous studies are underway to examine the biology of and genetic alterations in SCCHN that will lead to additional markers for use as rapid, noninvasive screening methods for individuals at high risk for primary or recurrent SCCHN. Our goal is to minimize morbidity and mortality from SCCHN by identifying useful predictors of disease and recurrence risk and response to therapy to implement earlier detection and more effective prevention and/or treatment strategies.
BACKGROUND: Cytogenetic alterations underlie the development of squamous cell carcinomas of the head and neck (SCCHN). Because many of the molecular genetic changes in SCCHN result from chromosomal alterations, a complete perspective on the genetic changes in tumors requires a basic introduction to cytogenetics. This review presents a brief description of the latest cytogenetic techniques and a description of chromosomal alterations in SCCHN, their molecular correlates, and clinical implications. RESULTS: The most frequent cytogenetic alterations in SCCHN are gains of 3q, 8q, 9q, 20q, 7p, 11q13, and 5p and losses of 3p, 9p, 21q, 5q, 13q, 18q, and 8p. The karyotypes often provide an explanation for the mechanism by which the molecular genetic alterations arose. For example, the coordinate gains and losses involving whole arms of chromosomes 3, 5, 7, 8, and 9 often result from isochromosome formation. In addition, apparent allelic imbalances may not represent loss of heterozygosity but gene amplification. These results suggest that cytogenetic analysis is valuable for placing the molecular genetic findings in perspective at the cellular level. CONCLUSIONS: Cytogenetic endpoints may be useful tools for dissecting clinical differences in tumor behavior and response to therapy. Numerous studies are underway to examine the biology of and genetic alterations in SCCHN that will lead to additional markers for use as rapid, noninvasive screening methods for individuals at high risk for primary or recurrent SCCHN. Our goal is to minimize morbidity and mortality from SCCHN by identifying useful predictors of disease and recurrence risk and response to therapy to implement earlier detection and more effective prevention and/or treatment strategies.
Authors: Roberto A Lleras; Leslie R Adrien; Richard V Smith; Benjamin Brown; Naheed Jivraj; Christopher Keller; Cathy Sarta; Nicolas F Schlecht; Thomas M Harris; Geoffrey Childs; Michael B Prystowsky; Thomas J Belbin Journal: Am J Pathol Date: 2011-05 Impact factor: 4.307
Authors: Jason S White; Joel L Weissfeld; Camille C R Ragin; Karen M Rossie; Christa Lese Martin; Michele Shuster; Chandramohan S Ishwad; John C Law; Eugene N Myers; Jonas T Johnson; Susanne M Gollin Journal: Oral Oncol Date: 2006-11-16 Impact factor: 5.337
Authors: Aloysius J Klingelhutz; Qining Qian; Stacia L Phillips; Francoise A Gourronc; Benjamin W Darbro; Shivanand R Patil Journal: Virology Date: 2005-09-30 Impact factor: 3.616
Authors: Verena L Bauer; Herbert Braselmann; Michael Henke; Dominik Mattern; Axel Walch; Kristian Unger; Michael Baudis; Silke Lassmann; Reinhard Huber; Johannes Wienberg; Martin Werner; Horst F Zitzelsberger Journal: J Mol Med (Berl) Date: 2008-09-23 Impact factor: 4.599
Authors: Madhav Sankunny; Rahul A Parikh; Dale W Lewis; William E Gooding; William S Saunders; Susanne M Gollin Journal: Genes Chromosomes Cancer Date: 2013-11-25 Impact factor: 5.006
Authors: G Mondal; A Tripathi; N Bhattacharya; N Sikdar; A Roy; A Sengupta; B Roy; C K Panda; S Roychoudhury Journal: J Clin Pathol Date: 2003-07 Impact factor: 3.411
Authors: Curtis R Pickering; Jiexin Zhang; Suk Young Yoo; Linnea Bengtsson; Shhyam Moorthy; David M Neskey; Mei Zhao; Marcus V Ortega Alves; Kyle Chang; Jennifer Drummond; Elsa Cortez; Tong-Xin Xie; Di Zhang; Woonbok Chung; Jean-Pierre J Issa; Patrick A Zweidler-McKay; Xifeng Wu; Adel K El-Naggar; John N Weinstein; Jing Wang; Donna M Muzny; Richard A Gibbs; David A Wheeler; Jeffrey N Myers; Mitchell J Frederick Journal: Cancer Discov Date: 2013-04-25 Impact factor: 39.397